| N total | Any OCa | Chlordane | DDT | Lindane | Aldrin | Heptachlor | Toxaphene | Dieldrin | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N exposed | RR | 95% CI | N exposed | RR | 95% CI | N exposed | RR | 95% CI | N exposed | RR | 95% CI | N exposed | RR | 95% CI | N exposed | RR | 95% CI | N exposed | RR | 95% CI | N exposed | RR | 95% CI | ||
All Cancer Sitesc | 3,204 | 287 | 0.96 | 0.85–1.08 | 160 | 0.99 | 0.84–1.16 | 158 | 0.98 | 0.83–1.15 | 46 | 0.91 | 0.68–1.22 | 41 | 1.12 | 0.82–1.53 | 36 | 1.06 | 0.76–1.48 | 29 | 1.05 | 0.73–1.52 | 17 | 1.02 | 0.63–1.65 |
  Solid tumors | |||||||||||||||||||||||||
  Bladder | 103 | 4 | 0.64 | 0.23–1.77 | 1 | _ | _ | 3 | 0.83 | 0.26–2.67 | 1 | _ | _ | 0 | _ | _ | 0 | _ | _ | 1 | _ | _ | 0 | _ | _ |
  Colon | 236 | 28 | 1.19 | 0.80–1.75 | 18 | 1.42 | 0.87–2.32 | 16 | 1.17 | 0.70–1.95 | 3 | 0.79 | 0.25–2.49 | 6 | 1.73 | 0.76–3.91 | 4 | 1.24 | 0.46–3.36 | 3 | 1.31 | 0.42–4.12 | 4 | 2.41 | 0.89–6.53 |
  Glioma | 44 | 11 | 3.52 | 1.72–7.21 | 4 | 1.81 | 0.64–5.12 | 2 | _ | _ | 3 | 4.45 | 1.36–14.55 | 1 | _ | _ | 2 | _ | _ | 2 | _ | _ | 0 | _ | _ |
  Kidney | 71 | 6 | 0.89 | 0.38–2.08 | 3 | 0.85 | 0.26–2.72 | 5 | 1.41 | 0.56–3.57 | 0 | _ | _ | 1 | _ | _ | 0 | _ | _ | 2 | _ | _ | 0 | _ | _ |
  Lung | 203 | 15 | 0.70 | 0.41–1.20 | 10 | 0.90 | 0.47–1.71 | 10 | 0.84 | 0.44–1.59 | 2 | _ | _ | 2 | _ | _ | 1 | _ | _ | 5 | 2.13 | 0.87–5.21 | 2 | _ | _ |
  Melanoma (cutaneous) | 145 | 12 | 1.08 | 0.59–1.97 | 4 | 0.63 | 0.23–1.72 | 5 | 0.88 | 0.36–2.18 | 2 | _ | _ | 3 | 2.20 | 0.69–7.02 | 3 | 2.40 | 0.75–7.64 | 1 | _ | _ | 1 | _ | _ |
  Pancreas | 55 | 7 | 1.33 | 0.59–2.97 | 3 | 1.03 | 0.32–3.34 | 1 | _ | _ | 3 | 3.70 | 1.15–12.0 | 1 | _ | _ | 1 | _ | _ | 0 | _ | _ | 0 | _ | _ |
  Rectum | 69 | 8 | 1.27 | 0.60–2.70 | 6 | 1.80 | 0.77–4.21 | 6 | 1.79 | 0.76–4.22 | 0 | _ | _ | 1 | _ | _ | 1 | _ | _ | 1 | _ | _ | 0 | _ | _ |
  Stomach | 26 | 5 | 2.61 | 0.96–7.11 | 1 | _ | _ | 3 | 2.64 | 0.76–9.15 | 1 | _ | _ | 1 | _ | _ | 0 | _ | _ | 0 | _ | _ | 0 | _ | _ |
  Thyroid | 54 | 5 | 0.66 | 0.26–1.63 | 4 | 0.97 | 0.36–2.67 | 1 | _ | _ | 0 | _ | _ | 1 | _ | _ | 1 | _ | _ | 0 | _ | _ | 0 | _ | _ |
  Lymphohematopoietic malignancies | |||||||||||||||||||||||||
  NHL | 233 | 28 | 1.23 | 0.82–1.83 | 17 | 1.35 | 0.82–2.22 | 17 | 1.35 | 0.81–2.22 | 6 | 1.60 | 0.71–3.60 | 1 | _ | _ | 3 | 1.03 | 0.33–3.24 | 3 | 1.49 | 0.48–4.68 | 0 | _ | _ |
  Multiple Myeloma | 42 | 8 | 2.01 | 0.91–4.42 | 6 | 2.71 | 1.12–6.55 | 4 | 1.75 | 0.61–5.01 | 1 | _ | _ | 0 | _ | _ | 1 | _ | _ | 1 | _ | _ | 0 | _ | _ |
  Myeloid Leukemia | 34 | 4 | 1.26 | 0.44–3.65 | 3 | 1.82 | 0.55–6.09 | 3 | 1.66 | 0.49–5.56 | 0 | _ | _ | 0 | _ | _ | 1 | _ | _ | 0 | _ | _ | 0 | _ | _ |
  Female specific sites | |||||||||||||||||||||||||
  Breast | 1,214 | 99 | 0.89 | 0.72–1.09 | 56 | 0.93 | 0.71–1.22 | 52 | 0.89 | 0.67–1.18 | 17 | 0.88 | 0.54–1.42 | 11 | 0.88 | 0.48–1.59 | 11 | 0.93 | 0.51–1.68 | 5 | 0.49 | 0.20–1.18 | 6 | 1.06 | 0.48–2.38 |
  ER + PR+ | 736 | 64 | 0.94 | 0.73–1.23 | 36 | 0.98 | 0.70–1.37 | 33 | 0.93 | 0.65–1.33 | 9 | 0.75 | 0.39–1.45 | 8 | 1.00 | 0.50–2.02 | 8 | 1.05 | 0.52–2.11 | 2 | _ | _ | 3 | 0.83 | 0.27–2.60 |
  ER-PR- | 202 | 15 | 0.82 | 0.48–1.40 | 9 | 0.90 | 0.46–1.76 | 7 | 0.76 | 0.36–1.63 | 4 | 1.22 | 0.45–3.30 | 2 | _ | _ | 2 | _ | _ | 1 | _ | _ | 3 | 3.55 | 1.12–11.18 |
  ER + PR- | 125 | 8 | 0.65 | 0.32–1.35 | 5 | 0.78 | 0.32–1.92 | 4 | 0.61 | 0.22–1.67 | 2 | _ | _ | 0 | _ | _ | 0 | _ | _ | 1 | _ | _ | 0 | _ | _ |
  Ovarian | 106 | 9 | 0.65 | 0.30–1.61 | 7 | 1.05 | 0.40–2.89 | 5 | 0.77 | 0.20–2.46 | 2 | _ | _ | 2 | _ | _ | 2 | _ | _ | 1 | _ | _ | 1 | _ | _ |
  Uterine | 276 | 20 | 0.83 | 0.50–1.32 | 10 | 0.80 | 0.40–1.50 | 10 | 0.82 | 0.42–1.56 | 2 | _ | _ | 4 | 1.50 | 0.60–4.06 | 3 | 1.12 | 0.40–3.51 | 2 | _ | _ | 1 | _ | _ |